Lipid Differences In Two Hispanic Ischemic Stoke Populations

OBJECTIVE: To compare lipid profiles among ischemic stroke (IS) patients in a predominantly Caribbean-Hispanic population in Miami and a Mestizo Hispanic population in Mexico City. BACKGROUND: Significant differences in stroke mortality, risk factors and IC subtypes have been described between Hispanics and other subgroups. No study has systematically examined differences in lipid profiles across different Hispanic groups. DESIGN/METHODS: We analyzed IS Hispanic patients with complete baseline fasting lipid profile enrolled contemporaneously in the prospective registries of 2 tertiary care teaching hospitals in Mexico City and Miami. Demographic, risk factors, medications, TOAST subtype, and first fasting lipid profile were compared. Vascular risk factor definitions were standardized. Multiple lineal logistic regression analysis was performed to compare lipid fractions. RESULTS: A total of 560 patients (324 from Mexico and 236 from Miami) were analyzed. Mexicans, were significantly younger (58.1 vs. 67.4 years), had a lower frequency of hypertension (53.4% vs. 79.7%), and lower body mass index (27 vs. 28.5). There was a trend towards greater prevalence of diabetes in Mexicans (31.5 vs. 24.6%, p=.07). Antilipidemics was more common in Miami Hispanics (18.6 vs. 9.4%). Mexicans had lower total cholesterol (TC) levels (169.9 ± 46.1 vs. 179.9 ± 48.8 mg/dl), low density lipoprotein (LDL) (92.3 ±37.1 vs. 108.2±40.8 mg/dl), non-high-density lipoprotein cholesterol (124.8±46.2 vs. 137.8±47.6 mg/dl) and lower lipid ratios (TC/HDL 4.2±1.6 vs. 4.6±1.8 and LDL/HDL 2.3±1.2 vs. 2.8±1.3). Mexicans had higher triglyceride levels (166.9±123.9 vs. 149.2±115.2 mg/dl). High-density lipoprotein (HDL) was similar. These differences remained significant after adjusting for age, sex, hypertension, diabetes, body mass index, smoking, stroke subtype and statin use. CONCLUSIONS: We found significant differences in lipid fractions, with lower LDL levels and higher TG levels in Mexicans. These findings highlight the heterogeneity of dyslipidemia among the Hispanic race-ethnic group. The underlying genetic and environmental contributions to these differences need to be further explored. Disclosure: Dr. Arauz has nothing to disclose. Dr. Romano has received personal compensation for activities with NovaVision. Dr. Romano holds stock and/or stock options in NovaVision. Dr. Romano has received research support from NovaVision. Dr. Ruiz-Navarro has nothing to disclose. Dr. Rundek has nothing to disclose. Dr. Shang has nothing to disclose. Dr. Ruiz-Navarro has nothing to disclose. Dr. Dong has nothing to disclose. Dr. Koch has nothing to disclose. Dr. Rojas has nothing to disclose. Dr. Katsnelson has nothing to disclose. Dr. Hernandez has nothing to disclose. Dr. Sacco has nothing to disclose.